Skip to main content
. Author manuscript; available in PMC: 2015 Dec 1.
Published in final edited form as: Clin Cancer Res. 2014 Oct 7;20(23):6006–6015. doi: 10.1158/1078-0432.CCR-14-1415

Table 1.

Clinical information for the nineteen subjects enrolled including age, mammographic breast density, menopause status, initial pathological diagnosis/receptor status, initial tumor size (region of interest, ROI), and surgical pathology outcome (complete or in-complete response) after treatment. Breast Density is defined as almost entirely fat (F), scattered fibro glandular densities (S), heterogeneously dense (H), and extremely dense (E).

Pt. Id age Meno-pause Breast Density Initial Path. (ER/PR/Her2) Size/ROI (mm) Treatment regimen Surgical path.
1 36 neg S IDC/DCIS
ER+/PR−/Her2+
65×37×71 TAC pCR
2 51 pos S IDC
ER−/PR−/Her2−
44×32×43 TAC pCR
3 41 neg H IDC
ER+/PR+/Her2+
53×22×50 TAC pCR
4 30 neg H IDC
ER−/PR−/Her2−
36 TAC pCR
5 52 pos H IDC
ER−/PR−/Her2+
100×70×50 FEC-Herceptin/Taxol-Herceptin pCR
6 63 pos H IDC/DCIS
ER+/PR+/Her2+
90×70×40 TAC pCR
7 60 pos S IDC/DCIS
ER−/PR−/Her2+
39×26×42 Taxol-Herceptin/FEC-Herceptin pCR
8 52 neg E IDC
ER−/PR−/Her2−
34×45×100 TAC pCR
9 66 pos H IDC/DCIS
ER−/PR−/Her2+
59×43×53 Taxol-Herceptin/FEC-Herceptin pCR
10 30 neg H IDC
ER−/PR−/Her2−
40×26×40 Taxol pIR
11 52 neg E IDC
ER+/PR+/Her2−
58×34×45 Taxol pIR
12 62 pos H IDC
ER+/PR+/Her2−
70×50×50 Adriamycin/cyclophosphamide/taxotere pIR
13 70 pos S IDC/DCIS
ER−/PR−/Her2+
63×28×30 Taxol-Herceptin/FEC-Herceptin pIR
14 53 neg E ILC
ER+/PR+/Her2−
76×45×79 TAC pIR
15 27 neg H IDC
ER+/PR+/Her2−
61×18×41 TAC pIR
16 53 neg H IDC
ER+/PR+/Her2+
62×46×87 Taxol-Herceptin/FEC-Herceptin pIR
17 50 neg H IDC
ER+/PR+/Her2+
40 Abraxane/Avastin pIR
18 56 pos H IDC
ER+/PR+/Her2+
55×34×52 TAC pIR
19 38 neg S IDC/DCIS
ER+/PR+/Her2−
84×93×50 TAC pIR

Breast Density- S: scatter; H: Heterogamous dense; E: extremely dense. Initial pathological results- IDC: invasive ductal carcinoma; DCIS: ductal carcinoma in situ.